Overview

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Status:
NOT_YET_RECRUITING

Trial end date:
2031-12-30

Target enrollment:

Participant gender:

Summary

This is a phase II trial exploring the maintenance therapy with trastuzumab combined with pyrotinib or dalpiciclib and endocrine therapy in HER2-positive advanced breast cancer based on different hormone receptor (HR) statuses following trastuzumab rezetecan (T-DXh, SHR-A1811) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC) patients.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Collaborators:

Chinese PLA General Hospital
Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Anastrozole
dalpiciclib
exemestane
Fulvestrant
Goserelin
Leuprolide
pyrotinib
Trastuzumab